Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
Clinical trial NCT03161353 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03161353
- Sponsor
- MedSIR
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-26
- Primary completion
- 2023-11-01
- Enrollment
- 377
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.